MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash acquired in
connection with the merger
$24,992K
Proceeds from exercise of
stock options
$532K
Net cash provided by
financing activities
$22,703K
Canceled cashflow
$2,821K
Net (decrease)
increase in cash and cash...
-$10,880K
Canceled cashflow
$22,703K
Stock-based compensation
expense
$1,399K
Accounts payable and
accrued expenses
$919K
Interest accrued on
convertible notes
$651K
Depreciation and
amortization expense
$95K
Non-cash lease expense
$72K
Maturities of short-term
investments
$21,402K
Payments for merger
transaction costs
$2,821K
Net cash used in
operating activities
-$23,499K
Canceled cashflow
$3,136K
Net cash used in
investing activities
-$10,084K
Canceled cashflow
$21,402K
Net loss
-$18,214K
Change in fair value of
convertible notes
-$7,810K
Prepaid expenses and
other assets
$308K
Accretion of net discounts
on short-term...
$200K
Operating lease
liabilities
-$103K
Purchases of short-term
investments
$31,486K
Back
Back
Cash Flow
source: myfinsight.com
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)